Scientific Shows Spotlight OGM’s Utility for Most cancers

• At a sponsored workshop, Su Yang from The College of Texas MD Anderson Most cancers Middle will current case research that show the flexibility of the optical genome mapping (OGM) workflow to detect pathogenic structural and replica quantity variants related to hematological most cancers analysis
• Dr. Ying Zhou from The Johns Hopkins College College of Drugs and Dr. Wahab Khan from Dartmouth Hitchcock Medical Middle will every lead academic classes on the utility of OGM throughout most cancers cytogenetic analysis functions

SAN DIEGO, July 02, 2024 (GLOBE NEWSWIRE) — Bionano Laboratories, a medical laboratory companies enterprise of Bionano Genomics, Inc. (Nasdaq: BNGO), at the moment introduced that optical genome mapping (OGM) shall be featured in three scientific displays on the 2024 joint annual assembly for the American Society for Scientific Laboratory Science (ASCLS), the Affiliation of Genetic Technologists (AGT), and the Society of American Federal Medical Laboratory Scientists (SAFMLS). The convention, which brings collectively laboratory professionals and {industry} companions affiliated with three skilled societies for networking and academic classes centered on chemistry, microbiology, hematology, molecular diagnostics and cytogenetics, shall be held July 8-12, 2024, in Pittsburgh, Pennsylvania and on-line.

At a sponsored scientific workshop titled “Revolutionizing hematological illness: unraveling genomic mysteries with optical genome mapping,” Su Yang, CG (ASCP), from The College of Texas MD Anderson Most cancers Middle, will current most cancers analysis case research that show OGM’s means to detect structural abnormalities in hematological samples at excessive sensitivity and determination.

A session titled “Scientific utilities of optical genome mapping at medical cytogenetic labs,” led by Ying Zhou, MD, PhD, FACMG, of The Johns Hopkins College College of Drugs, will cowl the flexibility of the OGM workflow to detect structural and replica quantity variants related to most cancers analysis.

Wahab Khan, PhD, FACMG, from Dartmouth Hitchcock Medical Middle, will current at a session titled “Organising optical genome mapping in your cytogenetic laboratory: factors for consideration in evaluation and take a look at validation,” the place he’ll cowl the implementation and validation of OGM for most cancers cytogenetic analysis functions.

“We’re happy to see numerous classes at this joint convention from main medical facilities that spotlight OGM as a cutting-edge software for molecular and cytogenetic analysis, because of its excessive sensitivity and determination and easy workflow. We imagine laboratory professionals throughout the globe will proceed to undertake and make the most of the OGM workflow because of its potential to positively influence most cancers and different analysis functions,” commented Erik Holmlin, PhD, president and chief government officer of Bionano.

Extra particulars on the convention will be discovered right here.

About Bionano Laboratories:

Bionano Laboratories offers entry to genetic solutions and help using cutting-edge applied sciences to advance the way in which the world sees the genome.  Its medical diagnostics companies provide optical genome mapping (OGM) testing that mixes a complete testing portfolio with considerate and accessible help choices. Bionano Laboratories additionally gives direct entry to OGM for functions throughout primary, translational and medical analysis. For extra data, go to www.bionanolaboratories.com

About Bionano

Bionano is a supplier of genome evaluation options that may allow researchers and clinicians to disclose solutions to difficult questions in biology and medication. The Firm’s mission is to remodel the way in which the world sees the genome by means of optical genome mapping (OGM) options, diagnostic companies and software program. The Firm gives OGM options for functions throughout primary, translational and medical analysis. The Firm additionally gives an industry-leading, platform-agnostic genome evaluation software program answer, and nucleic acid extraction and purification options utilizing proprietary isotachophoresis (ITP) know-how. By means of its Lineagen, Inc. d/b/a Bionano Laboratories enterprise, the Firm additionally gives OGM-based diagnostic testing companies.

For extra data, go to www.bionano.com, www.bionanolaboratories.com or www.purigenbio.com.

Ahead-Wanting Statements of Bionano Genomics

This press launch incorporates forward-looking statements throughout the which means of the Non-public Securities Litigation Reform Act of 1995. Phrases similar to “means,” “imagine,” “potential,” “will,” and comparable expressions (in addition to different phrases or expressions referencing future occasions, situations or circumstances) convey uncertainty of future occasions or outcomes and are meant to determine these forward-looking statements. Ahead-looking statements embody statements relating to our intentions, beliefs, projections, outlook, analyses or present expectations regarding, amongst different issues, OGM’s means to detect pathogenic structural and replica quantity variants related to hematological most cancers analysis; OGM’s means to detect structural abnormalities in hematological samples at excessive sensitivity and determination; OGM’s utility throughout most cancers cytogenetic analysis functions; the utility of OGM for analysis within the areas reported within the displays given and the posters made accessible on the 2024 joint annual assembly for ASCLS, AGT, and SAFMLS, and the expansion and adoption of OGM to be used in hematologic analysis functions. Every of those forward-looking statements entails dangers and uncertainties. Precise outcomes or developments could differ materially from these projected or implied in these forward-looking statements. Elements that will trigger such a distinction embody the dangers and uncertainties related to: world and macroeconomic occasions, similar to latest and potential financial institution failures, provide chain disruptions, world pandemics, inflation, and the continued conflicts between Ukraine and Russian and Israel and Hamas, on our enterprise and the worldwide economic system; common market situations; modifications within the aggressive panorama and the introduction of aggressive applied sciences or enhancements to present applied sciences; failure of OGM’s means to detect pathogenic structural and replica quantity variants related to hematological most cancers analysis; failure of OGM’s means to detect structural abnormalities in hematological samples at excessive sensitivity and determination; failure of OGM’s utility throughout most cancers cytogenetic analysis functions; failure of researchers to undertake OGM; failure of our OGM options to supply the anticipated advantages for and contributions to the areas reported within the displays given and posters made accessible on the 2024 joint annual assembly for ASCLS, AGT, and SAFMLS; future examine outcomes contradicting the outcomes reported within the displays given and posters made accessible on the 2024 joint annual assembly for ASCLS, AGT, and SAFMLS; modifications in our strategic and business plans; our means to acquire enough financing to fund our strategic plans and commercialization efforts; our means to successfully handle our makes use of of money, and our means to proceed as a “going concern”; the flexibility of medical and analysis establishments to acquire funding to help adoption or continued use of our applied sciences; and the dangers and uncertainties related to our enterprise and monetary situation on the whole, together with the dangers and uncertainties described in our filings with the Securities and Trade Fee, together with, with out limitation, our Annual Report on Kind 10-Ok for the 12 months ended December 31, 2023 and in different filings subsequently made by us with the Securities and Trade Fee. All forward-looking statements contained on this press launch converse solely as of the date on which they have been made and are primarily based on administration’s assumptions and estimates as of such date. We don’t undertake any obligation to publicly replace any forward-looking statements, whether or not on account of the receipt of latest data, the prevalence of future occasions or in any other case.

CONTACTS

Firm Contact:

Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionano.com

Investor Relations:

David Holmes
Gilmartin Group
+1 (858) 888-7625
IR@bionano.com